Abemaciclib plus endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes

被引：0
|
作者：
Johnston, S. [1 ]
Toi, M. [2 ]
O'Shaughnessy, J. [3 ]
Rastogi, P. [4 ,5 ]
Campone, M. [6 ]
Neven, P. [7 ]
Huang, C. S. [8 ]
Huober, J. [9 ]
Jaliffe, G. Garnica [10 ]
Cicin, I. [11 ]
Tolaney, S. [12 ]
Goetz, M. P. [13 ]
Rugo, H. [14 ]
Senkus, E. [15 ]
Testa, L. [16 ]
Del Mastro, L. [17 ]
Shimizu, C. [18 ]
Wei, R. [19 ]
Shahir, A. [19 ]
Munoz, M. [19 ]
Antonio, B. San [19 ]
Andre, V. [19 ]
Harbeck, N. [20 ]
Martin, M. [21 ]
机构：
[1] Royal Marsden Hosp, London, England
[2] Kyoto Univ, Grad Sch Med, Kyoto, Japan
[3] Baylor Univ, Med Ctr, Dallas, TX USA
[4] Univ Pittsburgh, NSABP NRG Oncol, Pittsburgh, PA USA
[5] Univ Pittsburgh, UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[6] Inst Cancerol Ouest, St Herblain, France
[7] Univ Ziekenhuis Leuven, Leuven, Belgium
[8] Natl Taiwan Univ Hosp, Taipei, Taiwan
[9] Kantonsspital St Gallen, St Gallen, Switzerland
[10] Grp Med Camino SC, Mexico City, Mexico
[11] Trakya Univ, Fac Med, Edirne, Turkiye
[12] Dana Farber Canc Inst, Boston, MA USA
[13] Mayo Clin, Rochester, MN USA
[14] Univ Calif San Francisco, San Francisco, CA USA
[15] Med Univ Gdansk, Gdansk, Poland
[16] Inst Canc Estado Sao Paulo ICESP, Sao Paulo, Brazil
[17] Univ Genoa, IRCCS Osped Policlin San Martino, Genoa, Italy
[18] Natl Ctr Global Hlth & Med, Tokyo, Japan
[19] Eli Lilly & Co, Indianapolis, IN USA
[20] Univ Munich, Munich, Germany
[21] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
来源：
BREAST | 2023年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P017
引用
收藏
页码：S22 / S23
页数：2
相关论文
共 28 条
  • [1] Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes
    Johnston, Stephen
    Toi, Masakazu
    O'Shaughnessy, Joyce
    Rastogi, Priya
    Campone, Mario
    Neven, Patrick
    Huang, Chiun Sheng
    Huober, Jens
    Jaliffe, Georgina Garnica
    Cicin, Irfan
    Tolaney, Sara
    Goetz, Matthew P.
    Rugo, Hope
    Senkus, Elzbieta
    Testa, Laura
    Del Mastro, Lucia
    Shimizu, Chikako
    Wei, Ran
    Shahir, Ashwin
    Munoz, Maria
    Antonio, Belen San
    Andre, Valerie
    Harbeck, Nadia
    Martin, Miguel
    CANCER RESEARCH, 2023, 83 (05)
  • [2] Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes
    Harbeck, N.
    Rastogi, P.
    O'Shaughnessy, J.
    Boyle, F.
    Cortes, J.
    Rugo, H. S.
    Goetz, M. P.
    Hamilton, E. P.
    Huang, C.
    Senkus-Konefka, E.
    Tryakin, A.
    Neven, P.
    Huober, J.
    Wei, R. J.
    Andre, V.
    Munoz, M.
    Antonio, B. San
    Shahir, A.
    Jimenez, M. Martin
    Johnston, S. R. D.
    ANNALS OF ONCOLOGY, 2023, 34 : S1256 - S1256
  • [3] Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2-, High-risk Early Breast cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-year Efficacy Outcomes
    Andre, V.
    Harbeck, N.
    Rastogi, P.
    O'Shaughnessy, J.
    Boyle, F.
    Cortes, J.
    Rugo, H. S.
    Goetz, M. P.
    Hamilton, E.
    Huang, C. -s.
    Senkus, E.
    Tryakin, A.
    Neven, P.
    Huober, J.
    Wei, R.
    Munoz, M.
    Antonio, B. S.
    Shahir, A.
    Martin, M.
    Johnston, S.
    BREAST, 2025, 80
  • [4] Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes
    Reinisch, Mattea
    Harbeck, Nadia
    Rastogi, Priya
    O'shaughnessy, Joyce
    Boyle, Frances
    Cortes, Javier
    Rugo, Hope S.
    Hamilton, Erika
    Goetz, Matthew P.
    Huang, Chiun-Sheng
    Senkus, Elzbieta
    Trakin, Alexey
    Neven, Patrick
    Huober, Jens
    Ran, Wei
    Andre, Valerie
    Munoz-Fernandez, Maria
    Antonio, Belen San
    Shahir, Ashwin
    Martin, Miguel
    Johnston, Stephen
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 227 - 228
  • [5] Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
    Hamilton, Erika P.
    Kim, Jee Hyun
    Eigeliene, Natalja
    Mavroudis, Dimitrios
    Median, Dragos Mircea
    Marconato, Heloisa
    Shevnia, Serhii
    Ozyilkan, Ozgur
    Puig, Juan Manuel
    Shannon, Catherine M.
    Munoz, Maria
    San Antonio, Belen
    Wei, Ran
    O'Shaughnessy, Joyce
    Johnston, Stephen R. D.
    Guarneri, Valentina
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
    Loi, Sherene
    Johnston, Stephen R. D.
    Arteaga, Carlos L.
    Graff, Stephanie L.
    Chandarlapaty, Sarat
    Goetz, Matthew P.
    Desmedt, Christine
    Sasano, Hironobu
    Liu, Deli
    Rodrik-Outmezguine, Vanessa
    Sireci, Anthony
    Sandoval, Cynthia
    Won, Helen H.
    Litchfield, Lacey M.
    Turner, Nicholas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA507 - LBA507
  • [7] Prognostic Utility of ctDNA Detection in The monarchE Trial of Adjuvant Abemaciclib Plus Endocrine therapy (ET) in HR+, HER2-, Node-positive, High-risk Early Breast Cancer (EBC)
    Loi, S.
    Johnston, S.
    Arteaga, C.
    Graff, S.
    Chandarlapaty, S.
    Goetz, M.
    Desmedt, C.
    Sasano, H.
    Liu, D.
    Rodrik-Outmezguine, V.
    Sireci, A.
    Sandoval, C.
    Won, H.
    Litchfield, L.
    Turner, N.
    BREAST, 2025, 80
  • [8] Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
    Johnston, Stephen R. D.
    Harbeck, Nadia
    Hegg, Roberto
    Toi, Masakazu
    Martin, Miguel
    Shao, Zhi Min
    Zhang, Qing Yuan
    Martinez Rodriguez, Jorge Luis
    Campone, Mario
    Hamilton, Erika
    Sohn, Joohyuk
    Guarneri, Valentina
    Okada, Morihito
    Boyle, Frances
    Neven, Patrick
    Cortes, Javier
    Huober, Jens
    Wardley, Andrew
    Tolaney, Sara M.
    Cicin, Irfan
    Smith, Ian C.
    Frenzel, Martin
    Headley, Desiree
    Wei, Ran
    San Antonio, Belen
    Hulstijn, Maarten
    Cox, Joanne
    O'Shaughnessy, Joyce
    Rastogi, Priya
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34) : 3987 - 3998
  • [9] Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: a plain language summary of the monarchE study
    D. Johnston, Stephen R.
    Rugo, Hope S.
    Tolaney, Sara M.
    Fernandez, Maria Munoz
    Wei, Ran
    Martin, Miguel
    FUTURE ONCOLOGY, 2024, 20 (28) : 2037 - 2048
  • [10] Patient-reported outcomes (PROs) of Chinese patients (pts) in monarchE: Abemaciclib plus endocrine therapy (ET) in adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (EBC)
    Zhang, Q.
    Shen, K.
    Song, C.
    Ouyang, Q.
    Liu, Z.
    Liu, Q.
    Wang, X.
    Yang, Y.
    Qian, C.
    Shao, Z.
    ANNALS OF ONCOLOGY, 2022, 33 : S1432 - S1432
123